Interleukin-31 Expression and Relation to Disease Severity in Human Asthma.

Tianwen Lai,Dong Wu,Wen Li,Min Chen,Zhennan Yi,Dan Huang,Zhiliang Jing,Yingying Lü,Quanchao Lv,Dongming Li,Bin Wu
DOI: https://doi.org/10.1038/srep22835
IF: 4.6
2016-01-01
Scientific Reports
Abstract:Interleukin 31 (IL-31) is a novel T helper type 2 effector cytokine that plays an important role in the pathogenesis of allergic diseases. However, its role in human asthma remains unclear. The aim of this study was to measure IL-31 levels in the serum, bronchoalveolar lavage fluid (BALF) and bronchial tissue of asthmatics and healthy subjects and identify its possible correlation to disease severity. We quantified IL-31 levels in the serum of patients with asthma (n = 44), as well as in controls (n = 22). Of these subjects, 9 asthmatics and five controls underwent bronchoscopy with endobronchial biopsy and BALF collection. Our data showed that serum and BALF IL-31 levels were significantly elevated in patients with asthma compared with controls. Expressions of IL-31 and IL-31 receptor (IL-31RA and OSMR) were more prominent in the bronchial tissue in severe compared to mild asthma and controls. Serum IL-31 levels correlated positively with Th2 related cytokines (IL-5, IL-13 and TSLP), asthma severity or total serum immunoglobulin E (IgE) and inversely with asthma control and the forced expiratory volume in 1 second (FEV 1 ). The current data may provide insight into the underlying pathogenesis of asthma, in which IL-31 has an important pathogenic role.
What problem does this paper attempt to address?